HPC
DNTH icon

HM Payson & Co’s Dianthus Therapeutics DNTH Stock Holding History

HM Payson & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-63
Closed -$4K – 1074
2021
Q4 		$4K Buy
+63
New +$6.33K ﹤0.01% 963
2021
Q2 		– Sell
-89
Closed -$17K – 1103
2021
Q1 		$17K Hold
89
– – ﹤0.01% 792
2020
Q4 		$11K Sell
89
-21
-19% -$2.38K ﹤0.01% 855
2020
Q3 		$12K Buy
+110
New +$13K ﹤0.01% 803

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

HM Payson & Co's DNTH Position: Q1 2022 in Review

HM Payson & Co sold out of Dianthus Therapeutics (DNTH) in Q1 2022, closing a stake of 63 shares — an estimated $4K sold.

HM Payson & Co first reported a position in DNTH in Q3 2020 and held it in 4 quarters. The position peaked at $17K in Q1 2021. 93 funds tracked by Wall St. Rank hold DNTH as of Q1 2022.

  • HM Payson & Co reported no remaining Dianthus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • HM Payson & Co sold 63 Dianthus Therapeutics shares in Q1 2022, an estimated $4K.
  • HM Payson & Co first reported a position in Dianthus Therapeutics in Q3 2020 and held it in 4 quarters.
  • HM Payson & Co's Dianthus Therapeutics position peaked at $17K in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2022.

Based on HM Payson & Co's 13F filing for Q1 2022, filed 12 May 2022.